Bioventus Q1 Revenue $132.1 M Up 7%, EBITDA Rises 24%; CFO to Present at Goldman Sachs
BVS•Bioventus reported first-quarter revenue of $132.1 million, a 7% year-over-year increase, with adjusted EBITDA rising 24% to $24 million and EPS nearly doubling to $0.15. The company also announced CFO Mark Singleton will present at the Goldman Sachs Global Healthcare Conference on June 8.
1. Q1 2026 Financial Results
Bioventus reported first-quarter revenue of $132.1 million, up 7% year-over-year, with adjusted EBITDA rising 24% to $24 million and adjusted EPS increasing to $0.15, nearly doubling the prior-year quarter. The company raised its full-year adjusted EPS and cash-flow guidance on the strength of these results.
2. CFO to Present at Goldman Sachs Conference
Mark Singleton, Bioventus Senior Vice President and CFO, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 at 4:00 p.m. ET. Investors can access a live webcast and replay via the Investors section of Bioventus’ website.
